Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial - Concepedia

Concepedia

Publication | Open Access

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

DOI Full Paper Access

52

Citations

20

References

2019

Year

Graham Jackson, Faith E. Davies, Charlotte Pawlyn, David A. Cairns, Alina Striha, Corinne Collett, Anna Waterhouse, John R. Jones, Bhuvan Kishore, Mamta Garg,

The Lancet Haematology

Abstract

Cancer Research UK, Celgene, Amgen, Merck, Myeloma UK.

References

	Year	Citations

Page 1